-
1Academic Journal
المساهمون: Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Plateforme de métabolomique, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa)-Université Paris Cité (UPCité), Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA, University Medical Center Utrecht and Princess Maxima Center, Utrecht, The Netherlands, Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, Munich, Germany, Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA, Sandra and Edward Meyer Cancer Center, New York, New York, USA, Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA, GK is supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT), Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, Fondation pour la Recherche Médicale (FRM), a donation by Elior, European Joint Programme on Rare Diseases (EJPRD) Wilsonmed, European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444, project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue), The ERA4 Health Cardinoff Grant Ener-LIGHT, European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures GOMS associated with cancer incidence, prognosis and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878 : Project Acronym: Neutrocure, project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation), National support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen), Hevolution Network on Senescence in Aging (reference HF-E Einstein Network), Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology ANR-18-IDEX-0001, a Cancer Research ASPIRE Award from the Mark Foundation, PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030), Seerave Foundation, SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001., ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-22-CE14-0066,VIVORUSH,Le système RUSH : un système chemo-génétique pour la manipulation in vivo de circuits de communication.(2022), ANR-23-CE44-0030,COPPERMAC,Ciblage du cuivre mitochondrial pour moduler l'inflammation(2023), ANR-23-R4HC-0006,Ener-LIGHT,Energizing the failing heart(2023), ANR-21-ESRE-0028,ONCO-PHENO-SCREEN,Next-generation phenotypic screening for oncological applications(2021), European Project: 825410, H2020-EU.3.1., H2020-EU.3.1.2.,ONCOBIOME (2019), European Project: 320339,EC:FP7:ERC,ERC-2012-ADG_20120314,IMMUNODEATH(2013)
المصدر: ISSN: 0007-9235 ; EISSN: 1542-4863.
مصطلحات موضوعية: cancer immunotherapy chemotherapy immune checkpoint blockade radiation therapy targeted therapy tumor-infiltrating lymphocytes 2, cancer immunotherapy, chemotherapy, immune checkpoint blockade, radiation therapy, targeted therapy, tumor-infiltrating lymphocytes 2, [SDV]Life Sciences [q-bio]
Relation: info:eu-repo/grantAgreement//825410/EU/Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response./ONCOBIOME; info:eu-repo/grantAgreement/EC/FP7/320339/EU/Immunogenic cell death in anticancer therapy/IMMUNODEATH
-
2Academic Journal
المساهمون: Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Plateforme de métabolomique, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa)-Université Paris Cité (UPCité), Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA, University Medical Center Utrecht and Princess Maxima Center, Utrecht, The Netherlands, Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, Munich, Germany, Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA, Sandra and Edward Meyer Cancer Center, New York, New York, USA, Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA, GK is supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT), Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, Fondation pour la Recherche Médicale (FRM), a donation by Elior, European Joint Programme on Rare Diseases (EJPRD) Wilsonmed, European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444, project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue), The ERA4 Health Cardinoff Grant Ener-LIGHT, European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures GOMS associated with cancer incidence, prognosis and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878 : Project Acronym: Neutrocure, project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation), National support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen), Hevolution Network on Senescence in Aging (reference HF-E Einstein Network), Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology ANR-18-IDEX-0001, a Cancer Research ASPIRE Award from the Mark Foundation, PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030), Seerave Foundation, SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001., ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-22-CE14-0066,VIVORUSH,Le système RUSH : un système chemo-génétique pour la manipulation in vivo de circuits de communication.(2022), ANR-23-CE44-0030,COPPERMAC,Ciblage du cuivre mitochondrial pour moduler l'inflammation(2023), ANR-23-R4HC-0006,Ener-LIGHT,Energizing the failing heart(2023), ANR-21-ESRE-0028,ONCO-PHENO-SCREEN,Next-generation phenotypic screening for oncological applications(2021), European Project: 825410, H2020-EU.3.1., H2020-EU.3.1.2.,ONCOBIOME (2019), European Project: 320339,EC:FP7:ERC,ERC-2012-ADG_20120314,IMMUNODEATH(2013)
المصدر: ISSN: 0007-9235 ; EISSN: 1542-4863.
مصطلحات موضوعية: cancer immunotherapy chemotherapy immune checkpoint blockade radiation therapy targeted therapy tumor-infiltrating lymphocytes 2, cancer immunotherapy, chemotherapy, immune checkpoint blockade, radiation therapy, targeted therapy, tumor-infiltrating lymphocytes 2, [SDV]Life Sciences [q-bio]
Relation: info:eu-repo/grantAgreement//825410/EU/Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response./ONCOBIOME; info:eu-repo/grantAgreement/EC/FP7/320339/EU/Immunogenic cell death in anticancer therapy/IMMUNODEATH
-
3Academic Journal
المساهمون: Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Plateforme de métabolomique, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa)-Université Paris Cité (UPCité), Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA, University Medical Center Utrecht and Princess Maxima Center, Utrecht, The Netherlands, Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, Munich, Germany, Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA, Sandra and Edward Meyer Cancer Center, New York, New York, USA, Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA, GK is supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT), Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, Fondation pour la Recherche Médicale (FRM), a donation by Elior, European Joint Programme on Rare Diseases (EJPRD) Wilsonmed, European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444, project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue), The ERA4 Health Cardinoff Grant Ener-LIGHT, European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures GOMS associated with cancer incidence, prognosis and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878 : Project Acronym: Neutrocure, project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation), National support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen), Hevolution Network on Senescence in Aging (reference HF-E Einstein Network), Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology ANR-18-IDEX-0001, a Cancer Research ASPIRE Award from the Mark Foundation, PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030), Seerave Foundation, SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001., ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-22-CE14-0066,VIVORUSH,Le système RUSH : un système chemo-génétique pour la manipulation in vivo de circuits de communication.(2022), ANR-23-CE44-0030,COPPERMAC,Ciblage du cuivre mitochondrial pour moduler l'inflammation(2023), ANR-23-R4HC-0006,Ener-LIGHT,Energizing the failing heart(2023), ANR-21-ESRE-0028,ONCO-PHENO-SCREEN,Next-generation phenotypic screening for oncological applications(2021), European Project: 825410, H2020-EU.3.1., H2020-EU.3.1.2.,ONCOBIOME (2019), European Project: 320339,EC:FP7:ERC,ERC-2012-ADG_20120314,IMMUNODEATH(2013)
المصدر: ISSN: 0007-9235 ; EISSN: 1542-4863.
مصطلحات موضوعية: cancer immunotherapy chemotherapy immune checkpoint blockade radiation therapy targeted therapy tumor-infiltrating lymphocytes 2, cancer immunotherapy, chemotherapy, immune checkpoint blockade, radiation therapy, targeted therapy, tumor-infiltrating lymphocytes 2, [SDV]Life Sciences [q-bio]
Relation: info:eu-repo/grantAgreement//825410/EU/Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response./ONCOBIOME; info:eu-repo/grantAgreement/EC/FP7/320339/EU/Immunogenic cell death in anticancer therapy/IMMUNODEATH
-
4Academic Journal
المساهمون: Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France, Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa)-Université Paris Cité (UPCité), Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA, University Medical Center Utrecht and Princess Maxima Center, Utrecht, The Netherlands, Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, Munich, Germany, Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA, Sandra and Edward Meyer Cancer Center, New York, New York, USA, Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA, GK is supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT), Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, Fondation pour la Recherche Médicale (FRM), a donation by Elior, European Joint Programme on Rare Diseases (EJPRD) Wilsonmed, European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444, project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue), The ERA4 Health Cardinoff Grant Ener-LIGHT, European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures GOMS associated with cancer incidence, prognosis and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878 : Project Acronym: Neutrocure, project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation), National support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen), Hevolution Network on Senescence in Aging (reference HF-E Einstein Network), Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology ANR-18-IDEX-0001, a Cancer Research ASPIRE Award from the Mark Foundation, PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030), Seerave Foundation, SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001., ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-22-CE14-0066,VIVORUSH,Le système RUSH : un système chemo-génétique pour la manipulation in vivo de circuits de communication.(2022), ANR-23-CE44-0030,COPPERMAC,Ciblage du cuivre mitochondrial pour moduler l'inflammation(2023), ANR-23-R4HC-0006,Ener-LIGHT,Energizing the failing heart(2023), ANR-21-ESRE-0028,ONCO-PHENO-SCREEN,Next-generation phenotypic screening for oncological applications(2021), European Project: 825410, H2020-EU.3.1., H2020-EU.3.1.2.,ONCOBIOME (2019), European Project: 320339,EC:FP7:ERC,ERC-2012-ADG_20120314,IMMUNODEATH(2013)
المصدر: ISSN: 0007-9235 ; EISSN: 1542-4863.
مصطلحات موضوعية: cancer immunotherapy chemotherapy immune checkpoint blockade radiation therapy targeted therapy tumor-infiltrating lymphocytes 2, cancer immunotherapy, chemotherapy, immune checkpoint blockade, radiation therapy, targeted therapy, tumor-infiltrating lymphocytes 2, [SDV]Life Sciences [q-bio]
Relation: info:eu-repo/grantAgreement//825410/EU/Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response./ONCOBIOME; info:eu-repo/grantAgreement/EC/FP7/320339/EU/Immunogenic cell death in anticancer therapy/IMMUNODEATH; hal-04606001; https://hal.science/hal-04606001; https://hal.science/hal-04606001/document; https://hal.science/hal-04606001/file/Manuscript.pdf
-
5Academic Journal
المساهمون: Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris Sciences et Lettres (PSL)-Université Paris Sciences et Lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Plateforme de métabolomique, Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS)-Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Cancer Research and Personalized Medicine - CARPEM Paris (SIRIC CARPEM), Hôpital Européen Georges Pompidou APHP (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpital Cochin AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Necker - Enfants Malades AP-HP, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut national du cancer (INCa)-Université Paris Cité (UPCité), Department of Radiation Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, Ohio, USA, University Medical Center Utrecht and Princess Maxima Center, Utrecht, The Netherlands, Comprehensive Cancer Center München, Technical University München & Ludwig Maximilian University, Munich, Germany, Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA, Sandra and Edward Meyer Cancer Center, New York, New York, USA, Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA, GK is supported by the Ligue contre le Cancer (équipe labellisée), Agence National de la Recherche (ANR-22-CE14-0066 VIVORUSH, ANR-23-CE44-0030 COPPERMAC, ANR-23-R4HC-0006 Ener-LIGHT), Association pour la recherche sur le cancer (ARC), Cancéropôle Ile-de-France, Fondation pour la Recherche Médicale (FRM), a donation by Elior, European Joint Programme on Rare Diseases (EJPRD) Wilsonmed, European Research Council Advanced Investigator Award (ERC-2021-ADG, Grant No. 101052444, project acronym: ICD-Cancer, project title: Immunogenic cell death (ICD) in the cancer-immune dialogue), The ERA4 Health Cardinoff Grant Ener-LIGHT, European Union Horizon 2020 research and innovation programmes Oncobiome (grant agreement number: 825410, Project Acronym: ONCOBIOME, Project title: Gut OncoMicrobiome Signatures GOMS associated with cancer incidence, prognosis and prediction of treatment response, Prevalung (grant agreement number 101095604, Project Acronym: PREVALUNG EU, project title: Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception), Neutrocure (grant agreement number 861878 : Project Acronym: Neutrocure, project title: Development of “smart” amplifiers of reactive oxygen species specific to aberrant polymorphonuclear neutrophils for treatment of inflammatory and autoimmune diseases, cancer and myeloablation), National support managed by the Agence Nationale de la Recherche under the France 2030 programme (reference number 21-ESRE-0028, ESR/Equipex+ Onco-Pheno-Screen), Hevolution Network on Senescence in Aging (reference HF-E Einstein Network), Institut National du Cancer (INCa), Institut Universitaire de France, LabEx Immuno-Oncology ANR-18-IDEX-0001, a Cancer Research ASPIRE Award from the Mark Foundation, PAIR-Obésité INCa_1873, the RHUs Immunolife and LUCA-pi (ANR-21-RHUS-0017 and ANR-23-RHUS-0010, both dedicated to France Relance 2030), Seerave Foundation, SIRIC Cancer Research and Personalized Medicine (CARPEM, SIRIC CARPEM INCa-DGOS-Inserm-ITMO Cancer_18006 supported by Institut National du Cancer, Ministère des Solidarités et de la Santé and INSERM). This study contributes to the IdEx Université de Paris Cité ANR-18-IDEX-0001., ANR-18-IDEX-0001,Université de Paris,Université de Paris(2018), ANR-22-CE14-0066,VIVORUSH,Le système RUSH : un système chemo-génétique pour la manipulation in vivo de circuits de communication.(2022), ANR-23-CE44-0030,COPPERMAC,Ciblage du cuivre mitochondrial pour moduler l'inflammation(2023), ANR-23-R4HC-0006,Ener-LIGHT,Energizing the failing heart(2023), ANR-21-ESRE-0028,ONCO-PHENO-SCREEN,Next-generation phenotypic screening for oncological applications(2021), European Project: 825410, H2020-EU.3.1., H2020-EU.3.1.2.,ONCOBIOME (2019), European Project: 320339,EC:FP7:ERC,ERC-2012-ADG_20120314,IMMUNODEATH(2013)
المصدر: ISSN: 0007-9235 ; EISSN: 1542-4863.
مصطلحات موضوعية: cancer immunotherapy chemotherapy immune checkpoint blockade radiation therapy targeted therapy tumor-infiltrating lymphocytes 2, cancer immunotherapy, chemotherapy, immune checkpoint blockade, radiation therapy, targeted therapy, tumor-infiltrating lymphocytes 2, [SDV]Life Sciences [q-bio]
Relation: info:eu-repo/grantAgreement//825410/EU/Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response./ONCOBIOME; info:eu-repo/grantAgreement/EC/FP7/320339/EU/Immunogenic cell death in anticancer therapy/IMMUNODEATH